US-12618073-B1 - Composition for regulating production of interfering ribonucleic acid

US12618073B1US 12618073 B1US12618073 B1US 12618073B1US-12618073-B1

Abstract

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for the translation of a target biomolecule, such as platelet-derived growth factor receptor beta (PDGFRB). The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.

Inventors

Bradley G. Thompson

Assignees

Wyvern Pharmaceuticals Inc.

Dates

Publication Date: 20260505
Application Date: 20250904

Claims (3)

1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO. 2.
2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.
3 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO. 3.

Description

This application contains a Sequence Listing electronically submitted via Patent Center to the United States Patent and Trademark Office as an XML Document file entitled “G10074847P1US-SequenceListing.xml” created on 2025 Sep. 3 and having a size of 15,920 bytes. The information contained in the Sequence Listing is incorporated by reference herein. TECHNICAL FIELD The present disclosure generally relates to compositions for regulating the production of micro-interfering ribonucleic acid (miRNA). In particular, the present disclosure relates to compositions for regulating gene expression and consequently, the production of miRNA that will suppress the expression of platelet-derived growth factor receptor beta (PDGFRB). BACKGROUND Platelet-derived growth factor receptor beta (PDGFRB) is a cell surface receptor tyrosine kinase protein that regulates cell growth by binding to platelet-derived growth factor. Excessive expression of PDGFRB can promote tumour growth. As such, it may be desirable to establish therapies, treatments and/or interventions that reduce PDGFRB expression in order to prevent or treat diseases caused by excessive PDGFRB expression. SUMMARY Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for the translation of a target biomolecule, and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in the bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a molecule such as PDGFRB. In some embodiments of the present disclosure, the compositions comprise a plasmid of deoxyribonucleic acid (DNA) that includes one or more insert sequences of nucleotides that encode for the production of miRNA and a backbone sequence of nucleic acids that facilitates the introduction of the one or more insert sequences into one or more of a subject's cells where it is expressed and/or replicated. Expression of the one or more insert sequences by one or more cells of the subject results in an increased production of the miRNA and, therefore, decreased translation and/or production of the target biomolecule by one or more of the subject's cells. Some embodiments of the present disclosure relate to compositions that upregulate the production of miRNA that degrades, or causes degradation of, or inactivates, or causes the inactivation of, the target mRNA of the target biomolecule. Some embodiments of the present disclosure relate to a recombinant plasmid (RP). In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 2. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences that encode a miRNA sequence that targets the mRNA of PDGFRB. Some embodiments of the present disclosure relate to a method of making a composition/target cell complex. The method comprises a step of administering an RP comprising SEQ ID NO. 1 and SEQ ID NO. 2 to a target cell in order to form the composition/target cell complex, wherein the composition/target cell complex causes the target cell to increase the production of one or more sequences of miRNA that decreases the production of a target biomolecule. Embodiments of the present disclosure relate to at least one approach for inducing the endogenous production of one or more sequences of miRNA that target and silence mRNA of a target biomolecule, for example PDGFRB. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of PDGFRB, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA. DETAILED DESCRIPTION Unless defined otherwise, all technical and scientific terms used therein have the meanings that would be commonly understood by one of skill in the art in the context of the present description. Although any methods and materials similar or equivalent to those described therein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. All publications mentioned therein are incorporated therein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. As used therein, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. For example, reference to “a composition” includ